The abstract is read at the publisher; the summary is JClub's.
DGKE expression is reduced in kidney biopsies from patients with glomerular diseases, and lower DGKE is linked to worse kidney function and higher urinary migrasome levels.
- Why it matters: Podocyte injury and aberrant migration drive podocyte loss, yet effective podocyte-targeted therapies are still not available clinically. Identifying migration pathways could enable new cell-specific interventions.
- What they did: The study measured DGKE in patient biopsies and compared it with eGFR and urinary migrasome levels, then tested podocyte-specific DGKE overexpression in three mouse models (ADR-, PAN-, and STZ/HFD-induced nephropathy). It also mapped a mechanism via the uPAR/β3 integrin axis and downstream Rac1/Cdc42 signaling.
- The result: Podocyte-specific DGKE overexpression attenuated podocyte injury and proteinuria across all three mouse models, supporting DGKE as a migration-regulating therapeutic target. The uPAR/β3 integrin–Rac1/Cdc42 pathway is implicated in how DGKE controls podocyte migration.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.